Main Study Findings
On each of our 4 measures of symptomatic response, results were modestly more favorable among children who received amoxicillin-clavulanate than among those who received placebo. Three of the between-group differences were statistically significant (P values 0.01, 0.02, and 0.04, respectively); 1 was not (P = 0.14). More substantial were the differences favoring the amoxicillin-clavulanate group in the rates of clinical failure: by day 4–5, 4% versus 23%; and by day 10–12, 16% versus 51% (both P values <0.001). No child was categorized as having met our criteria for clinical failure on the basis of symptoms alone.
Pediatr Infect Dis J. 2013;32(7):745-747. © 2013
Lippincott Williams & Wilkins